<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230775</url>
  </required_header>
  <id_info>
    <org_study_id>AOP13007</org_study_id>
    <nct_id>NCT01230775</nct_id>
  </id_info>
  <brief_title>Anagrelide Retard vs. Placebo: Efficacy and Safety in &quot;At-risk&quot; Patients With Essential Thrombocythaemia</brief_title>
  <acronym>ARETA</acronym>
  <official_title>A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of &quot;Anagrelide Retard&quot; Versus Placebo in &quot;at Risk&quot; Subjects With Essential Thrombocythaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOP Orphan Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AOP Orphan Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, phase III, randomized, subject and sponsor-blinded, placebo-controlled&#xD;
      study to determine the treatment effect of &quot;Anagrelide retard&quot; in subjects with Essential&#xD;
      Thrombocythaemia (ET) at &quot;defined risk&quot; (definition of risk criteria: see Inclusion Criteria&#xD;
      Section 5.1) The study is planned as a 2-stage procedure according to Bauer and Köhne: After&#xD;
      recruitment of 140 subjects an interim analysis with re-assessment of sample size is planned&#xD;
      in an adaptive manner.&#xD;
&#xD;
      As the confirmatory analysis will be based on a time-to-event evaluation (i.e. time to 1st&#xD;
      clinically significant ET related event), there is no stipulated observation time identically&#xD;
      applying for all subjects. Yet, with an interim analysis being performed after having&#xD;
      recruited 140 subjects - which is expected to be reached after 1 year - the estimated&#xD;
      observation time for a subject in stage I will also be about 1 year. (Details are explained&#xD;
      in the section &quot;Statistical Considerations&quot;).&#xD;
&#xD;
      Subjects will be randomized in a 1:1 ratio to one of the following two arms:&#xD;
&#xD;
      Group A: Anagrelide retard Group B: Placebo&#xD;
&#xD;
      An a priori stratification is planned for the JAK-2 mutational status. For exploratory&#xD;
      purposes a post hoc stratification is used for obtaining covariate adjusted results, for the&#xD;
      following other potentially predictive factors: sex, age, Factor V Leiden, and BMI.&#xD;
&#xD;
      Dosing will be started with 1 tablet per day for week 1 and will be titrated up according to&#xD;
      response (platelet reduction) to 2 tablets in week 2. Dosing may be further increased or&#xD;
      decreased according to platelet response in week 3 and 4. However, the maximum dose is 4&#xD;
      tablets (=8mg) per day. After week 4, the maximum dose to achieve optimal platelet counts&#xD;
      (&lt;450 G/L) should be maintained (for visit schedule see study flow chart section IV).&#xD;
&#xD;
      To verify a treatment response, platelet counts must be evaluated at every visit. The&#xD;
      platelet count values will be withheld from the subjects for the duration of stage I or stage&#xD;
      II respectively. The subjects have to agree explicitly to this procedure by signing the&#xD;
      Informed Consent form.&#xD;
&#xD;
      This is a patient and sponsor-blinded clinical study. The trial medical is packaged in the&#xD;
      blinded fashion to keep the patient unaware (blinded) towards the actual treatment group they&#xD;
      were randomized to. The sponsor functions (including medical monitor, pharmacovigilance&#xD;
      manager, clinical project manager, trial data manager and trial statistician) with stay&#xD;
      blinded in the course of the study until the database lock. Randomization scheme will be&#xD;
      prepared by an independent statistician (not otherwise involved in the study), and will be&#xD;
      stored securely with no access to it by the sponsor functions mentioned above. The process of&#xD;
      randomization (provision of the individual drug-allocation information to the subjects) will&#xD;
      be carried out by a trained staff by Harrison, in adherence to the procedures to keep the&#xD;
      other blinded functions unaware of this information (blinded). Unblinding envelopes, which&#xD;
      contain the treatment code per patient number for identification of treatment in case when a&#xD;
      safety-relevant unblinding needed, will be stored at the sponsor's site. At the end of the&#xD;
      study, verification of the extent of maintaining the blind by checking if the envelopes have&#xD;
      been broken, will take place and will be properly documented. If the sealed envelope will&#xD;
      broken to provide treatment identification, the date of breaking the code, the initials of&#xD;
      the person who broke the code and the reason will be stated on the envelope.&#xD;
&#xD;
      The operational details on the blinding procedures are outlined in the relevant working&#xD;
      guidelines (ARETA Study Working Guideline for idv staff and ARETA Study Working Guideline for&#xD;
      Harrison, each in its current version).&#xD;
&#xD;
      Investigator will not be blinded in this study, i.e. in case of a medical need individual&#xD;
      patient management will be driven by the full knowledge of the trial related interventions.&#xD;
      For the case, the sponsor will need to unblind a patient (e.g. due to safety reasons), the&#xD;
      above mentioned (in this section) envelopes will be used.&#xD;
&#xD;
      Only treatment naïve subjects, in respect to cytoreductive drugs with confirmed diagnosis of&#xD;
      ET (centralized re-evaluation according to WHO, 2008; see Section 6.2.1) and assessment of&#xD;
      JAK-2 status (centralized re-evaluation of JAK-2 status; see Section 6.2.2) will be enrolled.&#xD;
&#xD;
      As described above, stage I of the study will be considered as closed as soon as 140 subjects&#xD;
      have been recruited. The duration of stage II depends on the result of the re-assessment of&#xD;
      sample size.&#xD;
&#xD;
      Once stage I is finished, stage I subjects will enter into an extension period for a maximum&#xD;
      of three years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 1st clinically significant ET related event</measure>
    <time_frame>beginning 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and safety</measure>
    <time_frame>end 2013</time_frame>
    <description>Efficacy&#xD;
reduction of platelet counts&#xD;
occurrence of change to &quot;high risk&quot; status (i.e. platelets &gt; 1.000 G/L or occurrence of an ET related event)&#xD;
number of subjects achieving a complete response&#xD;
Safety&#xD;
Adverse Events&#xD;
cardiovascular safety (assessed by ECG, ECHO, NT-proBNP or BNP)&#xD;
Quality of Life: SF-36</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Essential Thrombocythaemia</condition>
  <arm_group>
    <arm_group_label>Anagrelide retard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 1:&#xD;
1x1 tablet/d of &quot;Anagrelide retard&quot; (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.&#xD;
Week 2 &quot;Anagrelide retard&quot;: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.&#xD;
Week 3 - Week 4 &quot;Anagrelide retard&quot; In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.&#xD;
Maintenance Phase &quot;Anagrelide retard&quot; During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.&#xD;
Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 1:&#xD;
x1 tablet/d of Placebo will be administered in week 1.&#xD;
Placebo:&#xD;
x1 tablet/d of placebo will be administered in week 2.&#xD;
Placebo:&#xD;
In week 3 and week 4 the maximum dose is 4 tablets per day.&#xD;
Placebo:&#xD;
In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:&#xD;
Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagrelide retard</intervention_name>
    <description>Week 1:&#xD;
1x1 tablet/d of &quot;Anagrelide retard&quot; (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.&#xD;
Week 2 &quot;Anagrelide retard&quot;: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.&#xD;
Week 3 - Week 4 &quot;Anagrelide retard&quot; In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.&#xD;
Maintenance Phase &quot;Anagrelide retard&quot; During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.</description>
    <arm_group_label>Anagrelide retard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Week 1:&#xD;
x1 tablet/d of placebo will be administered in week 1.&#xD;
Week 2&#xD;
Placebo:&#xD;
x1 tablet/d of placebo will be administered in week 2.&#xD;
Week 3 - Week 4&#xD;
Placebo:&#xD;
In week 3 and week 4 the maximum dose is 4 tablets per day.&#xD;
Placebo:&#xD;
In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:&#xD;
Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give written informed consent prior to any study specific&#xD;
             procedures and able to comply with this protocol&#xD;
&#xD;
          2. Male or female subjects aged between 18 and 60 years,&#xD;
&#xD;
          3. Confirmed diagnosis of ET according to WHO-criteria 2008 (Appendix A) including&#xD;
             assessment of JAK-2 status (central re-evaluation).&#xD;
&#xD;
          4. Presence of predisposing risk factors for ET related events confirmed by clinical or&#xD;
             laboratory results:&#xD;
&#xD;
        Definition of subjects with potential risk for ET-related Events:&#xD;
&#xD;
        - Platelet count &lt; 1.000 G/L&#xD;
&#xD;
        Additionally at least ONE of the following criteria has to be fulfilled:&#xD;
&#xD;
          -  Subjects aged between 40 and 60 years or&#xD;
&#xD;
          -  Subjects with ET and disease duration &gt; 3 years (Diagnosis of ET has to be at least 3&#xD;
             years ago and confirmed at time of screening) or&#xD;
&#xD;
          -  Subjects with ONE of the following risk factors for thrombotic complications:&#xD;
&#xD;
               -  JAK- 2 positivity&#xD;
&#xD;
               -  Protein C and/or Protein S deficiency&#xD;
&#xD;
               -  Antithrombin III deficiency&#xD;
&#xD;
               -  Factor V Leiden or Prothrombin mutation&#xD;
&#xD;
               -  Cardiovascular risk factors:&#xD;
&#xD;
          -  Essential hypertension,&#xD;
&#xD;
          -  Smoking (&gt;5 cigarettes/d),&#xD;
&#xD;
          -  Obesity (BMI&gt;30),&#xD;
&#xD;
          -  Cholesterol (HDL/LDL ratio &lt; 4),&#xD;
&#xD;
          -  Hormone replacement therapy,&#xD;
&#xD;
          -  Hormonal contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of any other myeloproliferative disorder&#xD;
&#xD;
          2. High-risk status (age &gt; 60 years, platelet count ≥ 1.000 G/L, increase of platelet&#xD;
             count &gt; 300 G/L within 3 month, history of thrombotic/haemorrhagic or ischemic&#xD;
             complications).&#xD;
&#xD;
          3. Any known cause for a secondary thrombocytosis&#xD;
&#xD;
          4. Previous or current treatment of ET with cytoreductive therapy&#xD;
&#xD;
          5. Diagnosis of any malignancy, apart from ET, within the last 3 years&#xD;
&#xD;
          6. Known or suspected intolerance to the investigational product&#xD;
&#xD;
          7. Known or suspected congestive heart failure&#xD;
&#xD;
          8. WBC ≥ 15 G/L&#xD;
&#xD;
          9. Severe renal impairment (creatinine clearance &lt;30 ml/min)&#xD;
&#xD;
         10. Severe liver impairment (ALT or AST &gt;5 times normal)&#xD;
&#xD;
         11. Clinically significant abnormal laboratory values (excluding markers of essential&#xD;
             thrombocythaemia)&#xD;
&#xD;
         12. Poorly controlled diabetes mellitus&#xD;
&#xD;
         13. Infection with hepatitis B, hepatitis C or HIV&#xD;
&#xD;
         14. Subjects with a history of drug/alcohol abuse (within the previous 2 years)&#xD;
&#xD;
         15. Participation in another investigational study within 6 months prior to enrolment or&#xD;
             for a longer duration if specified in local regulations&#xD;
&#xD;
         16. Women of childbearing potential with inadequate contraception&#xD;
&#xD;
         17. Pregnant or lactating women (pregnancy test to be assessed within 7 days prior to&#xD;
             study treatment start)&#xD;
&#xD;
         18. Any significant psychiatric disorder that, in the opinion of the investigator, might&#xD;
             prohibit the understanding and giving of informed consent or that might prevent the&#xD;
             subject from completing the trial.&#xD;
&#xD;
        Women of childbearing potential with inadequate contraception; women with child-bearing&#xD;
        potential, receiving oral hormone contraception and aiming to participate in the study,&#xD;
        will have to apply an additional effective method of contraception during the study period;&#xD;
        male subjects, receiving investigational medicinal product, which have sexual intercourse&#xD;
        with females of childbearing potential, should use medically acceptable and reliable method&#xD;
        of contraception to prevent pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Grohmann-Izay, MD</last_name>
    <role>Study Director</role>
    <affiliation>AOP Orphan Pharmaceuticals AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin III, Universitätsklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialmedizinisches Zentrum Ost</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik für Innere Medizin I</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Dr Georgi Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment, &quot;Tokuda Hospital Sofia&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT &quot;Joan Pavel&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kauno Medicinos Universiteto Klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda Hospital</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Szpital Kliniczny im. A. Mieleckiego</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital Miejski</name>
      <address>
        <city>Torùn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologiczna, Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical County Hospital &quot;Dr. Constantin Opris&quot;</name>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Coltea&quot; Clinic Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Fundeni&quot; Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Emergency Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Clinic Hospital</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital Târgu Mureș</name>
      <address>
        <city>Târgu Mureș</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution Territorial Clinical</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology Research Center of RAMS</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian scientific Research Institute for Hematology and Transfusiology</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Institution of Healthcare</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urgent and Recovery Surgery n.a.</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kmelnitskiy Regional Hospital</name>
      <address>
        <city>Khmelnitskiy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Haematology and Transfusiology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Radiation Medicine AMS of Ukraine</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Blood Pathology Institute</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Slovenia</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

